These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 27484801

  • 1. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V.
    Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
    [Abstract] [Full Text] [Related]

  • 2. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
    Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou CM, Carey LA.
    JAMA Oncol; 2023 Apr 01; 9(4):490-499. PubMed ID: 36602784
    [Abstract] [Full Text] [Related]

  • 3. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S.
    JAMA Oncol; 2015 Jul 01; 1(4):448-54. PubMed ID: 26181252
    [Abstract] [Full Text] [Related]

  • 4. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.
    Ann Oncol; 2018 Jan 01; 29(1):170-177. PubMed ID: 29045543
    [Abstract] [Full Text] [Related]

  • 5. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S.
    Lancet Oncol; 2018 Jan 01; 19(1):40-50. PubMed ID: 29233559
    [Abstract] [Full Text] [Related]

  • 6. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M.
    Cancer Treat Rev; 2017 Jun 01; 57():8-15. PubMed ID: 28525810
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
    De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.
    Clin Cancer Res; 2020 Feb 01; 26(3):738-745. PubMed ID: 31653641
    [Abstract] [Full Text] [Related]

  • 8. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.
    Lancet Oncol; 2017 Apr 01; 18(4):545-554. PubMed ID: 28238593
    [Abstract] [Full Text] [Related]

  • 9. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, Ye J, Zhang S, Zhang H, Zhu S, Li T, Liu Y.
    Breast Cancer Res Treat; 2015 Nov 01; 154(2):239-49. PubMed ID: 26498019
    [Abstract] [Full Text] [Related]

  • 10. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
    Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.
    J Clin Oncol; 2016 Feb 20; 34(6):542-9. PubMed ID: 26527775
    [Abstract] [Full Text] [Related]

  • 11. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Ohara AM, Naoi Y, Shimazu K, Kagara N, Shimoda M, Tanei T, Miyake T, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2019 Feb 20; 173(3):533-543. PubMed ID: 30361874
    [Abstract] [Full Text] [Related]

  • 12. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
    Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA.
    JAMA Oncol; 2024 May 01; 10(5):603-611. PubMed ID: 38546612
    [Abstract] [Full Text] [Related]

  • 13. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH, Li CX, Liu M, Jiang JY.
    BMC Cancer; 2020 Nov 25; 20(1):1150. PubMed ID: 33238978
    [Abstract] [Full Text] [Related]

  • 14. Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy.
    Khoury T, Nagrale V, Opyrchal M, Peng X, Wang D, Yao S.
    Appl Immunohistochem Mol Morphol; 2018 Sep 25; 26(8):523-532. PubMed ID: 28187033
    [Abstract] [Full Text] [Related]

  • 15. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO.
    JAMA Oncol; 2017 Nov 09; 3(11):e172085. PubMed ID: 28750133
    [Abstract] [Full Text] [Related]

  • 16. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.
    Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J.
    Clin Cancer Res; 2014 Jan 15; 20(2):511-21. PubMed ID: 24443618
    [Abstract] [Full Text] [Related]

  • 17. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Kochi M, Iwamoto T, Niikura N, Bianchini G, Masuda S, Mizoo T, Nogami T, Shien T, Motoki T, Taira N, Tokuda Y, Doihara H, Matsuoka J, Fujiwara T.
    Breast Cancer Res Treat; 2018 Jan 15; 167(1):39-47. PubMed ID: 28905250
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.
    JAMA Oncol; 2016 Oct 01; 2(10):1287-1294. PubMed ID: 27281556
    [Abstract] [Full Text] [Related]

  • 19. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
    Ingold Heppner B, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S.
    Clin Cancer Res; 2016 Dec 01; 22(23):5747-5754. PubMed ID: 27189162
    [Abstract] [Full Text] [Related]

  • 20. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
    Swain SM, Tang G, Lucas PC, Robidoux A, Goerlitz D, Harris BT, Bandos H, Geyer CE, Rastogi P, Mamounas EP, Wolmark N.
    Breast Cancer Res Treat; 2019 Nov 01; 178(2):389-399. PubMed ID: 31428908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.